[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630160":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":30,"responsibleParty":50,"collaborators":52,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":11,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":11,"enrollmentInfo":64,"targetDuration":11,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":11,"overallStatus":33,"whyStopped":11,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Olistic Research Labs S.L.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active Product Arm","EXPERIMENTAL",null,[13],"Dietary Supplement: Drinkable multifactorial food supplement containing vitamins, minerals, amino acids, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women +45.",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo Arm","PLACEBO_COMPARATOR",[18],"Other: Placebo control",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DIETARY_SUPPLEMENT","Drinkable multifactorial food supplement containing vitamins, minerals, amino acids, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women +45.","Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, amino acids, plant extracts, and other bioactive compounds designed to support hair growth and scalp health in women +45.",[9],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"OTHER","Placebo control","Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile.",[15],[31],{"facility":32,"status":33,"city":34,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Grupo Dermatologico Y Estetico Pedro Jaen S.A.","RECRUITING","Madrid","28006","Spain","ES",{"type":39,"coordinates":40},"Point",[41,42],-3.70256,40.4165,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":11,"email":49},"Leyre Malet, PhD","CONTACT","+34 617862464","info@icmrresearch.com",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[53],{"name":32,"class":54},"UNKNOWN","100630160","efficacy-and-safety-of-a-drinkable-nutraceutical-for-hair-loss-in-patients-using-glp-1gip-receptor-agonists-100630160",false,"NCT07484061","Efficacy and Safety of a Drinkable Nutraceutical for Hair Loss in Patients Using GLP-1\u002FGIP Receptor Agonists","Evaluation of the Efficacy and Safety of a Drinkable Nutraceutical in Improving Hair Loss in Patients Treated With GLP-1\u002FGIP Receptor Agonists: a Double-blind, 1:1 Randomized, Placebo-controlled Study.","Inclusion Criteria:\n\n* Female gender.\n* Age \\>35 years.\n* Initiation of treatment with a GLP-1\u002FGIP agonist, or treatment duration \\\u003C 3 months, as per routine clinical practice in the endocrinology clinic.\n* Having signed the participant information sheet and the written informed consent and having been informed of the objective of the study.\n* Additional criteria to be included by the client.\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to any of the components of the product, or to a product from a similar category to the one being tested.\n* Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate to severe seborrheic dermatitis, eczema, cancer, etc.\n* Women presenting alopecia due to an underlying medical condition (hypothyroidism, anemia, lupus, etc.).\n* Pharmacological treatment that may promote the onset of telogen effluvium, initiated within the 3 months prior to study start (e.g., valproic acid, carbamazepine, phenytoin, selective serotonin reuptake inhibitors, oral anticoagulants, retinoids, beta-blockers). Patients who have undergone a dose change of these medications within the same period are also excluded.\n* Women with uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism) within the 6 months prior to study initiation.\n* Women who have used anti-hair loss products within the last 3 months.\n* Women who have initiated or undergone dermatological treatment for hair loss within the last 6 months (minoxidil, finasteride, PRP, mesotherapy, etc.).\n* Women who have undergone hair transplantation within the 18 months prior to study initiation.\n* Women who have initiated treatment with anxiolytics, antidepressants, amphetamines, ACE inhibitors, or iron within the last 3 months.\n* Women who initiated or discontinued hormonal treatment (oral contraceptives, oral or topical hormone replacement therapy, ovarian stimulation) within the 3 months prior to study initiation.\n* Pregnant women, postpartum women (within 6 months), breastfeeding women, or women planning to become pregnant during the study period.\n* Additional exclusion criteria to be specified by the sponsor.\n* Any condition that, in the investigator's opinion, makes participation in the study inappropriate.","FEMALE","35 Years",{"count":65,"type":66},40,"ESTIMATED","INTERVENTIONAL",[69],"NA","The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1\u002FGIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic© Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product throughout the treatment period.",[72],"Telogen Effluvium","2026-03-19",{"date":75,"type":76},"2026-03-23","ACTUAL",{"date":78,"type":76},"2026-03-16",{"date":80,"type":66},"2026-10-31",{"name":5,"class":6},1]